Literature DB >> 10668943

The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.

S Ataus1, A Citçi, B Alici, A U Onder, K Sönmezoğlu, A Erözenci, V Solok.   

Abstract

The cut-off value of serum prostate-specific antigen (PSA) level in prediction of bone metastases and the correlation of serum PSA with the clinical stage, grade, score and the rate of bone metastases have been investigated in cases of prostate cancer (PCa). The study population consisted of 160 patients with histologically proven PCa between April, 1993 and August, 1996. The negative predictive value and the sensitivity were the highest (94%) in patients with a serum PSA value less than 10 ng/ml. We claim that in patients with PSA values less than 10 ng/ml whole body bone scan is not necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10668943     DOI: 10.1023/a:1007163227968

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  23 in total

1.  Imaging of patients with stage D prostatic carcinoma.

Authors:  P McCarthy; H M Pollack
Journal:  Urol Clin North Am       Date:  1991-02       Impact factor: 2.241

2.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.

Authors:  M S Soloway; S W Hardeman; D Hickey; J Raymond; B Todd; S Soloway; M Moinuddin
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

3.  The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma.

Authors: 
Journal:  J Urol       Date:  1979-03       Impact factor: 7.450

4.  The histology and prognosis of prostatic cancer.

Authors:  G T Mellinger; D Gleason; J Bailar
Journal:  J Urol       Date:  1967-02       Impact factor: 7.450

5.  When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?

Authors:  S Haukaas; J Roervik; O J Halvorsen; M Foelling
Journal:  Br J Urol       Date:  1997-05

6.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

Authors:  F M Chybowski; J J Keller; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

7.  Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?

Authors:  Z Levran; J A Gonzalez; A C Diokno; S Z Jafri; B W Steinert
Journal:  Br J Urol       Date:  1995-06

8.  Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate.

Authors:  D L Schaffer; H P Pendergrass
Journal:  Radiology       Date:  1976-11       Impact factor: 11.105

9.  The role of bone scanning in the assessment of prostatic carcinoma.

Authors:  B McGregor; A G Tulloch; M F Quinlan; F Lovegrove
Journal:  Br J Urol       Date:  1978-05

10.  Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta.

Authors:  D S Ernst; J Hanson; P M Venner
Journal:  J Urol       Date:  1991-08       Impact factor: 7.450

View more
  3 in total

1.  Prostate-specific Antigen as a Risk Factor for Skeletal Metastasis in Native Ethnic African Men with Prostate Cancer: A Case-control Study.

Authors:  Ayman M Qureshi; Khalid Makhdomi; William Stones
Journal:  World J Nucl Med       Date:  2017 Jan-Mar

2.  Prostate-specific antigen cutoff value for ordering sodium fluoride positron emission tomography/computed tomography bone scan in patients with prostate cancer.

Authors:  Ismet Sarikaya; Ali Sarikaya; Abdelhamid H Elgazzar; Vuslat Yurut Caloglu; Prem Sharma; Ali Baqer; Murat Caloglu; Mahmoud Alfeeli
Journal:  World J Nucl Med       Date:  2018 Oct-Dec

3.  Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy.

Authors:  Koramadai Karuppusamy Kamaleshwaran; Bhagwant Rai Mittal; Chidambaram Natrajan Balasubramanian Harisankar; Anish Bhattacharya; Shrawan Kumar Singh; Arup K Mandal
Journal:  Indian J Nucl Med       Date:  2012-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.